Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
MYO1C is a urinary extracellular vesicle biomarker and mediator of podocyte injury in diabetic nephropathy
Zihao Zhao, Qianqian Yan, Sijie Zhou, Fengxun Liu, Yong Liu, Jingjing Ren, Shaokang Pan, Zhenjie Liu, Dongwei Liu, Zhangsuo Liu, Jiayu Duan
Zihao Zhao, Qianqian Yan, Sijie Zhou, Fengxun Liu, Yong Liu, Jingjing Ren, Shaokang Pan, Zhenjie Liu, Dongwei Liu, Zhangsuo Liu, Jiayu Duan
View: Text | PDF
Research Article Inflammation Nephrology

MYO1C is a urinary extracellular vesicle biomarker and mediator of podocyte injury in diabetic nephropathy

  • Text
  • PDF
Abstract

Type 2 diabetic nephropathy (T2DN) is a major complication of type 2 diabetes and a leading cause of chronic kidney disease. This study aimed to explore Myosin IC (MYO1C) as both a candidate biomarker and elucidate its role as a mechanistic mediator of podocyte injury in T2DN. Using urinary extracellular vesicle RNA biomarkers identified from a training and validation cohort of 33 type 2 diabetes and 40 patients with T2DN, we developed a machine learning diagnostic model for T2DN. The model achieved an AUC of 0.877 in validation and performed well in an independent test cohort with an AUC of 0.824. MYO1C was identified as the most influential feature in the final model. Mechanistic investigations in vitro and in vivo revealed that high glucose and high-fat conditions induced podocyte injury, inflammation, and apoptosis, with increased MYO1C expression. MYO1C knockdown in vitro and in vivo reduced podocyte damage and inflammatory responses. MYO1C overexpression enhanced p38, p-CREB, and TNF-α levels, while p38 inhibition mitigated these effects. These findings support MYO1C not only as a potential urinary biomarker for T2DN but also as a key pathogenic driver that promotes podocyte injury via p38 MAPK signaling.

Authors

Zihao Zhao, Qianqian Yan, Sijie Zhou, Fengxun Liu, Yong Liu, Jingjing Ren, Shaokang Pan, Zhenjie Liu, Dongwei Liu, Zhangsuo Liu, Jiayu Duan

×

Figure 4

Comprehensive analysis of high glucose and high fat effects on podocyte viability, EVs RNA expression, and molecular expression patterns in HPCs.

Options: View larger image (or click on image) Download as PowerPoint
Comprehensive analysis of high glucose and high fat effects on podocyte ...
(A) CCK-8 assay evaluating the effect of high glucose and high fat (HGHF) on HPCs cell viability over time. HPCs were treated with BSA (28.8 mM mannitol, control group [CON]) or various concentrations of PA (30 mM glucose, HG+PA group) for different durations. Statistical comparisons: “#” indicates significance between specific groups; “*” indicates significance at 48 hours compared with the CON group. **P < 0.01, ##P < 0.01. Data are presented as mean ± SEM from 3 independent experiments. (B) Characterization of HPCs-derived EVs, including representative TEM images (scale bar: 100 nm), NanoFCM particle size distribution histograms, and immunoblots of EV marker and negative marker proteins. (C) qPCR analysis of 5 differential RNAs in HPCs-derived EVs (left) and the corresponding HPCs (right). Data are presented as mean ± SEM from 3 independent experiments. Statistical comparisons were performed using 1-way ANOVA with Tukey’s multiple-comparison test. *P < 0.05, **P < 0.01, ***P < 0.001. (D) Immunoblots of specified proteins in HPCs under different treatment conditions. (E) qPCR analysis of mRNA expression levels for MYO1C, SYNPO, NPHS2, and TNF-α in HPCs treated with HGHF. Data are from 4 independent experiments. (F) Representative confocal images showing SYNPO (red) and MYO1C (green) expression and their colocalization in HPCs under different treatment conditions. Scale bar: 20 μm.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts